The MedTech funding mandate

The NHS Long Term Plan committed to accelerate the uptake of selected innovative medical devices, diagnostics and digital products to patients faster, by developing the MedTech Funding Mandate policy.

The proposal for this policy was consulted on in December 2019 with patient representatives, NHS providers, commissioners, charities, academics, delivery partners, consultants, independent health providers and industry. The consultation report is available here.

The MedTech Funding Mandate policy received strong support with clear recommendations on the criteria for inclusion technologies. The MedTech Funding Mandate policy launched on the 1 April 2021. The guidance for 2021/22 is published here.

In 2021/22 the policy supports devices, diagnostics or digital products that:

  • are effective: demonstrated through positive NICE guidance;
  • deliver material savings to the NHS: the benefits of the innovation are over £1 million over five years for the population of England;
  • are cost-saving in-year: NICE modelling demonstrates a net saving in the first 12 months of implementing the technology;
  • are affordable to the NHS: the budget impact should not exceed £20 million, in any of the first three years.

To minimise burden on the NHS at this time, it was agreed that for the first year of the policy only, technologies must have also been previously supported by the Innovation Technology Payment.

The technologies supported by the policy in 2021/22 are:

  1. placental growth factor-based testing– a blood test to rule out pre-eclampsia in pregnant women
  2. SecurAcath– for securing percutaneous catheters
  3. HeartFlow– creates a 3D model of a patient’s coronary arteries and assesses the extent and location of blockages
  4. gammaCore– a handheld device which alleviates the symptoms of severe cluster headaches

In 2021/22 all technologies covered by the MedTech Funding Mandate are CCG commissioned.

Together with technology suppliers we work with patients and our delivery partners, the Academic Health Science Networks (AHSNs) to support NHS organisations to implement the existing innovations, to understand local and regional issues and to share learning from NHS organisations who have already implemented the innovations. This helps to identify barriers to their uptake, such as duplicative procurement processes.

We expect hospitals and commissioning organisations to comply with the policy guidance where appropriate. We ask our AHSN delivery partners to work closely with commissioners, providers, clinicians, patient groups and others, to understand the impact of the policy and support its development.

Providers wishing to implement any of the supported technologies should contact their regional AHSN. Alternatively, for more information contact the innovation team (see contacts at the foot of the page).

In addition you can watch Matt Whitty, Director of Innovation, Research and Life Sciences and Chief Executive of AAC, and other policy leaders, discussing the MedTech Funding Mandate policy’s introduction. The videos provide an overview of the policy and the financial flow between NHS England and NHS Improvement, Trusts and CCGs, as well as an introduction to the first four products supported.

Technologies covered by the MedTech Funding Mandate in 2022/23

NICE have assessed all Medical Technology Guidance (MTG) and Diagnostic Guidance (DG) published up to and including 30 June 2021 to understand which technologies meet the criteria to be mandated from year two of the policy in April 1 2022.

The criteria, as published in the 2021/22 guidance document, is that the technologies must

  • have a positive NICE MTG or DG guidance
  • be cost saving within 3 years (demonstrated by a NICE Resource Impact tools)
  • not have a budget impact of more than £20 milion in any of the first 3 years

Between now and April 2022 we will engage with the technology suppliers who meet the criteria and other stakeholders to understand more about the technologies and we will publish further details about them in the Autumn.

Our FutureNHS collaboration platform will continue to be updated with information on the MedTech Funding Mandate policy. To request permission to access the platform or for any other related query you can contact the team by emailing: